Search results
Showing 691 to 705 of 9079 results
All NICE products on chronic liver disease. Includes any guidance, advice and quality standards.
All NICE products on neuroendocrine tumours. Includes any guidance.
All NICE products on acne. Includes any guidance.
This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.
View quality statements for QS75Show all sections
Sections for QS75
- Quality statements
- Quality statement 1: Intrapartum antibiotics
- Quality statement 2: Assessment for early-onset neonatal infection
- Quality statement 3: Prompt antibiotic treatment for neonatal infection
- Quality statement 4: Reassessing antibiotic treatment for neonatal infection
- Quality statement 5: Information and support for parents and carers
- Update information
- About this quality standard
This quality standard covers assessing and managing oesophago-gastric cancer in adults. It describes high-quality care in priority areas for improvement.
All NICE products on vaginal conditions. Includes any guidance.
Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.
All NICE products on inflammatory bowel disease. Includes any guidance, advice and quality standards.
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Initial education in adrenaline auto-injector use
- Quality statement 2: Referral to specialist allergy services after emergency treatment
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4: Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS97Show all sections
Sections for QS97
- Quality statements
- Quality statement 1: Documentation using the structured assessment guide
- Quality statement 2: Advice about carrying personal structured drug information
- Quality statement 3: Referral to specialist drug allergy services
- Quality statement 4: Recording drug allergy status in electronic medical records
- Quality statement 5: Updating information on drug allergy status
- Quality statement 6 (developmental): Prescription information on drug avoidance
- Update information
All NICE products on multiple sclerosis. Includes any guidance, advice and quality standards.
This webpage covers NICE guidelines on breast cancer. The table below presents the guidelines alphabetically with links to the surveillance report...
All NICE products on thyroid disorders. Includes any guidance.
All NICE products on parathyroid disorders. Includes any guidance.
All NICE products on osteoporosis. Includes any guidance, advice and quality standards.